[Effects of medium-term probucol treatment on plasma lipids and lipoproteins. 16 cases of type IIa and IIb hyperlipoproteinaemia (author's transl)].
Probucol was used to treat 16 patients with atherogenic hyperlipoproteinaemia. The duration of treatment varied between 30 days (16 patients) and 510 days (4 patients). The drug was found to be remarkably well tolerated, without any clinical or biological side-effects. There was an 8 to 13 p. cent reduction in plasma total cholesterol, a 4 to 17 p. cent reduction in LDL cholesterol and a very favorable increase (19 to 23 p. cent) in the HDL/LDL + VLDL cholesterol ratio. Little or no change was found in triglyceride and HDL cholesterol levels.
D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000627:therapeutic use*; D011341:Probucol / Q000009:adverse effects / Q000627:therapeutic use*
D008055:Lipids; D008074:Lipoproteins; D010636:Phenols; D002784:Cholesterol; D011341:Probucol
Effet du probucol à moyen terme sur les lipides et lipoprotéines plasmatiques. 16 observations d'hyperlipoprotéinémies de type IIa et IIb.